###begin article-title 0
###xml 92 100 <span type="species:ncbi:9606">Patients</span>
C-Peptide and Its C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients
###end article-title 0
###begin p 1
Recommended by Subrata Chakrabarti
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aims/hypothesis</italic>
###xml 333 340 333 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</italic>
###xml 885 892 885 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Results</italic>
###xml 1051 1052 1051 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1463 1488 1463 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conclusion/interpretation</italic>
###xml 1722 1724 1722 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1779 1780 1779 1780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1783 1784 1783 1784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1185 1193 <span type="species:ncbi:9606">patients</span>
Aims/hypothesis. Data now indicate that proinsulin C-peptide exerts important physiological effects and shows the characteristics of an endogenous peptide hormone. This study aimed to investigate the influence of C-peptide and fragments thereof on erythrocyte deformability and to elucidate the relevant signal transduction pathway. Methods. Blood samples from 23 patients with type 1 diabetes and 15 matched healthy controls were incubated with 6.6 nM of either human C-peptide, C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment comprising residues 11-19 of C-peptide, or randomly scrambled C-peptide. Furthermore, red blood cells from 7 patients were incubated with C-peptide, penta- and hexapeptides with/without addition of ouabain, EDTA, or pertussis toxin. Erythrocyte deformability was measured using a laser diffractoscope in the shear stress range 0.3-60 Pa. Results. Erythrocyte deformability was impaired by 18-25% in type 1 diabetic patients compared to matched controls in the physiological shear stress range 0.6-12 Pa (P < .01-.001). C-peptide, penta- and hexapeptide all significantly improved the impaired erythrocyte deformability of type 1 diabetic patients, while the middle fragment and scrambled C-peptide had no detectable effect. Treatment of erythrocytes with ouabain or EDTA completely abolished the C-peptide, penta- and hexapeptide effects. Pertussis toxin in itself significantly increased erythrocyte deformability. Conclusion/interpretation. C-peptide and its C-terminal fragments are equally effective in improving erythrocyte deformability in type 1 diabetes. The C-terminal residues of C-peptide are causally involved in this effect. The signal transduction pathway is Ca2+-dependent and involves activation of red blood cell Na+, K+-ATPase.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 305 307 305 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 420 421 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 982 983 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
During the past decade, several studies have provided evidence that C-peptide is a biologically active endogenous peptide. It binds specifically in nanomolar concentration to cell membranes [1], possibly to a G-protein-coupled receptor, resulting in internalisation of the peptide [2] and activation of Ca2+- and MAPK-dependent signalling pathways [3-6]. Cellular end-effects include stimulation and induction of both Na+, K+-ATPase, and eNOS as well as activation of a series of transcriptional fators [3, 7-10]. Studies in patients with type 1 diabetes who lack endogenous C-peptide production show that administration of C-peptide in replacement doses results in increased regional blood flow in several tissues [11-13] and amelioration of diabetes-induced functional and structural abnormalities of the peripheral nerves and the kidneys [14-16]. Not only the full-length native C-peptide but also its C-terminal pentapeptide fragment is reported to exert physiological effects [1, 4, 6, 17, 18].
###end p 5
###begin p 6
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 541 542 541 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 847 855 <span type="species:ncbi:9606">patients</span>
It is well established that diabetes is associated with reduced deformability of red blood cells [19-21]. This abnormality is of clinical significance in that it compromises the ability of red blood cells to pass through capillaries, reduces tissue perfusion, and impairs tissue oxygen supply [4, 22]. The mechanism underlying the decreased red cell compliance in diabetes is not well understood, but it has been shown that C-peptide is capable of restoring red cell deformability to normal levels, most likely via stimulation of red cell Na+, K+-ATPase [23]. The extent to which C-peptide fragments will do the same has not been determined. Consequently, the aim of this study was to examine the influence of C-peptide and its C-terminal fragments, as well as middle segments on the abnormal deformability of red blood cells from type 1 diabetes patients. In addition, aspects of a possible signal transduction pathway were evaluated.
###end p 6
###begin title 7
2. SUBJECTS, MATERIALS, AND METHODS
###end title 7
###begin title 8
2.1. Subjects
###end title 8
###begin p 9
###xml 92 99 92 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
 Blood samples were taken from 23 type 1 diabetes patients and 15 matched healthy controls (Table 1). Inclusion criteria were C-peptide serum level < 0.2 nmol/L, diabetes duration > 2 years, serum creatinine < 2 mg/dL, and no clinically relevant diabetic long-term complications. Hematocrit values were in the normal range for all patients and controls.
###end p 9
###begin title 10
2.2. Materials and methods
###end title 10
###begin p 11
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 394 397 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#964;</italic>
###xml 414 415 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 460 463 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#951;</italic>
###xml 477 478 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</italic>
###xml 514 515 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
 Laser diffractoscopy was performed using a Rheodyn SSD shear stress diffractometer (Myrenne GmbH, Roetgen, Germany). The method of laser diffractoscopy has been described in detail previously [21, 23]. In summary, a He-Ne-Laser detects deformation of erythrocytes between two parallel glass discs, one of which rotates resulting in defined shear stresses as per the following equation:  where tau = shear stress, r = laser beam distance from rotation center, eta = viscosity, h = height of gap between discs, and t = time.
###end p 11
###begin p 12
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</italic>
###xml 68 71 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#951;</italic>
Adjusting for equipment-specific values (r = 25 mm, h = 0.5 mm, and eta = 24 mPa), the equation is condensed to  where rpm = revolutions per minute.
###end p 12
###begin p 13
The applied shear stress range is electronically regulated and includes 8 levels (0.3 Pa; 0.6 Pa; 1.2 Pa; 3 Pa; 6 Pa; 12 Pa; 30 Pa; 60 Pa).
###end p 13
###begin p 14
The erythrocyte deformability measurement detects scattered-light intensities along orthogonal axes (A, B) of red blood cells within the laser diffraction light cone. The erythrocyte elongation index (EI) is calculated by the following equation:
###end p 14
###begin p 15
###xml 199 201 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
All experiments were carried out at 23degreesC, which was thermostatically regulated. Blood samples were collected using ammonium-heparinated vials and subsequently distributed to dextran medium (30 muL blood per 2 mL dextran). Stability tests were performed to exclude significant effects of storage time and/or serum glucose concentration on erythrocyte deformability measured by laser diffractoscopy (data not shown). All measurements of erythrocyte deformability were carried out before incubation with active ingredients as well as at 1, 30, and 60 minutes after incubation
###end p 15
###begin p 16
###xml 0 33 0 33 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="17">C-peptide and C-peptide fragments</title>
###xml 554 561 554 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 33 562 33 562 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="18"> Human C-peptide and all C-peptide fragments were provided by Creative Peptides (Stockholm, Sweden) at a purity of &gt;98%. C-peptide and its fragments were dissolved in phosphate buffer and incubations were made at 6.6 nmol/L. The incubation and mixing of probes were done smoothly to avoid external shear stress. The fragments used in this study were C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment including residues 11&#8211;19, and randomly scrambled C-peptide; their amino acid sequences are presented in <xref ref-type="table" rid="tab2">Table 2</xref>.</p>
###xml 0 562 0 562 <statement xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="17">C-peptide and C-peptide fragments</title><p textid="18"> Human C-peptide and all C-peptide fragments were provided by Creative Peptides (Stockholm, Sweden) at a purity of &gt;98%. C-peptide and its fragments were dissolved in phosphate buffer and incubations were made at 6.6 nmol/L. The incubation and mixing of probes were done smoothly to avoid external shear stress. The fragments used in this study were C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment including residues 11&#8211;19, and randomly scrambled C-peptide; their amino acid sequences are presented in <xref ref-type="table" rid="tab2">Table 2</xref>.</p></statement>
###xml 34 39 <span type="species:ncbi:9606">Human</span>
C-peptide and C-peptide fragments Human C-peptide and all C-peptide fragments were provided by Creative Peptides (Stockholm, Sweden) at a purity of >98%. C-peptide and its fragments were dissolved in phosphate buffer and incubations were made at 6.6 nmol/L. The incubation and mixing of probes were done smoothly to avoid external shear stress. The fragments used in this study were C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment including residues 11-19, and randomly scrambled C-peptide; their amino acid sequences are presented in Table 2.
###end p 16
###begin title 17
C-peptide and C-peptide fragments
###end title 17
###begin p 18
###xml 521 528 521 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 1 6 <span type="species:ncbi:9606">Human</span>
 Human C-peptide and all C-peptide fragments were provided by Creative Peptides (Stockholm, Sweden) at a purity of >98%. C-peptide and its fragments were dissolved in phosphate buffer and incubations were made at 6.6 nmol/L. The incubation and mixing of probes were done smoothly to avoid external shear stress. The fragments used in this study were C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment including residues 11-19, and randomly scrambled C-peptide; their amino acid sequences are presented in Table 2.
###end p 18
###begin p 19
###xml 0 7 0 7 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="20">Ouabain</title>
###xml 138 140 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 7 231 7 224 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="21"> Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo, USA). Treatment with ouabain was titrated to achieve a concentration of 1 <italic>&#956;</italic>mol/L. Incubations with and without C-peptide or fragments lasted 30 minutes at 23&#176;C.</p>
###xml 0 231 0 224 <statement xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="20">Ouabain</title><p textid="21"> Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo, USA). Treatment with ouabain was titrated to achieve a concentration of 1 <italic>&#956;</italic>mol/L. Incubations with and without C-peptide or fragments lasted 30 minutes at 23&#176;C.</p></statement>
Ouabain Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo, USA). Treatment with ouabain was titrated to achieve a concentration of 1 mumol/L. Incubations with and without C-peptide or fragments lasted 30 minutes at 23degreesC.
###end p 19
###begin title 20
Ouabain
###end title 20
###begin p 21
###xml 131 133 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
 Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo, USA). Treatment with ouabain was titrated to achieve a concentration of 1 mumol/L. Incubations with and without C-peptide or fragments lasted 30 minutes at 23degreesC.
###end p 21
###begin p 22
###xml 0 4 0 4 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="23">EDTA</title>
###xml 4 195 4 189 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="24"> Incubations with EDTA (1.6 mg/mL) with and without C-peptide or fragments lasted 30 minutes at 23&#176;C. Treatment with EDTA alone did not alter erythrocyte deformability (data not shown).</p>
###xml 0 195 0 189 <statement xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="23">EDTA</title><p textid="24"> Incubations with EDTA (1.6 mg/mL) with and without C-peptide or fragments lasted 30 minutes at 23&#176;C. Treatment with EDTA alone did not alter erythrocyte deformability (data not shown).</p></statement>
EDTA Incubations with EDTA (1.6 mg/mL) with and without C-peptide or fragments lasted 30 minutes at 23degreesC. Treatment with EDTA alone did not alter erythrocyte deformability (data not shown).
###end p 22
###begin title 23
EDTA
###end title 23
###begin p 24
 Incubations with EDTA (1.6 mg/mL) with and without C-peptide or fragments lasted 30 minutes at 23degreesC. Treatment with EDTA alone did not alter erythrocyte deformability (data not shown).
###end p 24
###begin p 25
###xml 0 15 0 15 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="26">Pertussis toxin</title>
###xml 99 101 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 15 150 15 143 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="27"> Pertussis toxin was obtained from Sigma-Aldrich. Treatment with pertussis toxin (1 <italic>&#956;</italic>g/mL) was conducted for 60 minutes at 37&#176;C.</p>
###xml 0 150 0 143 <statement xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="26">Pertussis toxin</title><p textid="27"> Pertussis toxin was obtained from Sigma-Aldrich. Treatment with pertussis toxin (1 <italic>&#956;</italic>g/mL) was conducted for 60 minutes at 37&#176;C.</p></statement>
Pertussis toxin Pertussis toxin was obtained from Sigma-Aldrich. Treatment with pertussis toxin (1 mug/mL) was conducted for 60 minutes at 37degreesC.
###end p 25
###begin title 26
Pertussis toxin
###end title 26
###begin p 27
###xml 84 86 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
 Pertussis toxin was obtained from Sigma-Aldrich. Treatment with pertussis toxin (1 mug/mL) was conducted for 60 minutes at 37degreesC.
###end p 27
###begin p 28
###xml 0 20 0 20 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="29">Statistical analysis</title>
###xml 195 196 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 205 206 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 20 272 20 270 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="30"> Results are expressed as the means &#177; SD. Gaussian distribution was checked by the Kolmogoroff-Smirnoff test. Statistical analysis were done by two-site ANOVA and Student's <italic>t</italic> test. A <italic>P</italic>-value of less than .05 was regarded as statistically significant.</p>
###xml 0 272 0 270 <statement xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="29">Statistical analysis</title><p textid="30"> Results are expressed as the means &#177; SD. Gaussian distribution was checked by the Kolmogoroff-Smirnoff test. Statistical analysis were done by two-site ANOVA and Student's <italic>t</italic> test. A <italic>P</italic>-value of less than .05 was regarded as statistically significant.</p></statement>
Statistical analysis Results are expressed as the means +/- SD. Gaussian distribution was checked by the Kolmogoroff-Smirnoff test. Statistical analysis were done by two-site ANOVA and Student's t test. A P-value of less than .05 was regarded as statistically significant.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 175 176 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 185 186 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
 Results are expressed as the means +/- SD. Gaussian distribution was checked by the Kolmogoroff-Smirnoff test. Statistical analysis were done by two-site ANOVA and Student's t test. A P-value of less than .05 was regarded as statistically significant.
###end p 30
###begin title 31
3. RESULTS
###end title 31
###begin p 32
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 300 301 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 475 482 473 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
Erythrocyte deformability was significantly decreased in type 1 diabetes patients compared to healthy controls over the full range of shear stress tested (Figure 1). In the physiological shear stress range (</=12 Pa), the difference between diabetic patients and healthy controls amounted to 18-25% (P < .01-.001) Incubation of the red cells from type 1 diabetes patients with C-peptide completely normalized the erythrocyte defortmability at all tested shear stress levels (Table 3). Incubation with the penta- and hexapeptides also resulted in significant improvements in erythrocyte deformability over the range of shear stress tested; the responses to C-peptide and the C-terminal peptides were similar and there were no statistically significant differences between these three treatment groups. In contrast, the middle fragment exerted no significant effect on the diabetes-induced abnormal erythrocyte deformability. Likewise and as expected, scrambled C-peptide with a random amino acid sequence had no beneficial effect on erythrocyte deformability.
###end p 32
###begin p 33
###xml 195 203 195 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Pretreatment of erythrocytes from patients with type 1 diabetes with ouabain or EDTA completely abolished the C-peptide-, penta- and hexapeptide-induced improvements in deformability as shown in Figure 2 for the pentapeptide at the shear stress 1.2 Pa. Similar results were obtained for all levels of shear stress. Pretreatment of erythrocytes with pertussis toxin in itself increased erythrocyte deformability significantly (P < .05) in the shear stress range of 0.6-12 Pa. Therefore, the possible influence of G-protein inactivation on the effects mediated by C-peptide and its fragments could not be evaluated.
###end p 33
###begin title 34
4. DISCUSSION
###end title 34
###begin p 35
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
The present results confirm and extend previous observations indicating that red blood cell deformability is compromised in diabetes [19-21] and that this abnormality can be corrected by C-peptide [23]. Thus, using whole blood samples and laser diffractoscopy, a method with high reproducibility (CV < 1%), erythrocyte deformability measured in blood samples from type 1 diabetes patients was found to be reduced by 18-25% over the physiological shear stress range (0.6-12 Pa), in keeping with previous results using the same methodology [23]. Exposing blood cells from the diabetic patients to 6.6 nM, C-peptide was found to fully normalize membrane deformability. We now show that not only the native, full length C-peptide but also its C-terminal penta- and hexapeptides possess this capability. In contrast, a middle segment comprising residues 11-19 of C-peptide had no effect. The specificity of the observed effects is attested by the finding that scrambled C-peptide, a control peptide with its residues assembled in random order, had no detectable effect.
###end p 35
###begin p 36
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 446 448 446 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1060 1064 <span type="species:ncbi:10116">rats</span>
The current results for the pentapeptide are in line with previous reports that it competes with C-peptide for cellular binding [1], that it elicits an increase in intracellular Ca2+-concentration [4], activates PKC isoforms, causes phosphorylation of ERK1/2 and JNK, and stimulates Na+, K+-ATPase activity [6, 17, 24]. Studies evaluating the pentapeptide's cellular binding/competition characteristics, its stimulatory effect on intracellular Ca2+-concentrations and ERK1/2 phosphorylation demonstrate that it is the N-terminal Glu-residue of the pentapeptide (Glu 27 of C-peptide) that is of primary importance for its bioactivity; alanine substitution of the other four residues has little or no effect on the pentapeptide's bioactivity [4, 25, 26]. Its bioactivity has been found to be similar to that of the native peptide both in the above in vitro studies and in invivo experiments evaluating its stimulatory effect on whole-body glucose utilization [18] and its inhibition of diabetes-induced glomerular hyperfiltration [27] in streptozotocin-diabetic rats.
###end p 36
###begin p 37
###xml 194 202 194 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 784 785 784 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 788 789 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
The C-terminal hexapeptide was found to be equally potent as the pentapeptide and the native C-peptide with regard to its amelioration of diabetes-induced abnormal red blood cell deformability (Figure 2). Only little information is available with regard to the physiology of the hexapeptide but the current findings are in line with previous observations that it is capable of stimulating Na+, K+-ATPase in renal tubular segments with potency similar to that of the pentapeptide [17]. In contrast to the findings for the two C-terminal segments, there was no indication that the middle fragment (residues 11-19) exerted a measurable effect on diabetes-induced abnormal red cell deformability. Variable results have been reported previously for middle fragments; mild stimulation of Na+, K+-ATPase in renal tubule segments [17] but no effect on glucose utilization under in vivo conditions [18] have been observed.
###end p 37
###begin p 38
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 582 584 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 624 625 624 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 628 629 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 729 730 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 733 734 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 456 462 <span type="species:ncbi:9986">rabbit</span>
###xml 745 750 <span type="species:ncbi:9606">human</span>
Exposing red blood cells from patients with type 1 diabetes to either oubain or EDTA resulted in complete abrogation of the normalizing effect by the penta- and hexapeptides or C-peptide on erythrocyte deformability. Evaluation of a G-protein involvement in the signalling pathway could not be carried out since exposure of the erythrocytes to pertussis toxin in itself resulted in alteration of red cell deformability in contrast to previous findings for rabbit erythrocytes [28]. Nevertheless, the results indicate that the beneficial effects of the peptides are mediated via a Ca2+-dependent stimulation of erythrocyte Na+, K+-ATPase, in analogy with the previously established signal transduction pathway for C-peptide and Na+, K+-ATPase in human renal tubular cells [24], even though the EDTA results may suggest that other metal ions also are of importance for the signal transduction [29].
###end p 38
###begin p 39
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 907 908 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1597 1599 1597 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1600 1602 1600 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1604 1606 1604 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1694 1696 1694 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1715 1717 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1516 1524 <span type="species:ncbi:9606">patients</span>
Exposure of erythrocytes to C-peptide and its C-terminal fragments is thus likely to result in augmented generation and release of ATP, as has been observed directly in the case of C-peptide and both normal and diabetic red blood cells [29]. ATP is a recognized stimulus of nitric oxide synthase of platelets and erythrocytes [30, 31]. Nitric oxide, besides being a potent vasodilator, is also effective in eliciting improved red blood cell deformability as a result of direct action of nitric oxide on the erythrocyte membrane [32, 33]. In addition, C-peptide-related improvement of red cell deformability may be mediated not via ATP but by direct stimulation of red cell nitric oxide synthase. The latter is functionally similar to that of endothelial cells [31], and C-peptide and most likely also its C-terminal fragments are known to stimulate and cause induction of endothelial nitric oxide synthase [8, 10]. The above mechanisms are likely to contribute to the maintenance of normal erythrocyte membrane plasticity and the extent to which they are modified in diabetes is unknown. However, irrespective of the exact mechanism involved, the present findings demonstrate that both C-peptide and its C-terminal fragments are capable of effectively normalizing the diabetes-induced reduction in red blood cell deformability. It is probable that this effect contributed importantly to the observed improvement in regional blood flow of skin, muscle, myocardium, and peripheral nerve in animals and type 1 diabetes patients, following administration of C-peptide to physiological concentrations [11-13, 34]. Furthermore, the beneficial clinical effects of C-peptide on early-stage neuropathy [14] and nephropathy [15] in type 1 diabetes may in part be related to correction of the abnormal red cell deformability and subsequently improved microcirculation. Further clinical trials are warranted document and define the role of C-peptide and its C-terminal fragments in the treatment and/or prevention of microvascular complications of type 1 diabetes.
###end p 39
###begin article-title 40
###xml 44 49 <span type="species:ncbi:9606">human</span>
Specific binding of proinsulin C-peptide to human cell membranes
###end article-title 40
###begin article-title 41
Cellular internalization of proinsulin C-peptide
###end article-title 41
###begin article-title 42
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 21 24 <span type="species:ncbi:10116">rat</span>
C-peptide stimulates rat renal tubular Na+, K+-ATPase activity in synergism with neuropeptide Y
###end article-title 42
###begin article-title 43
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells
###end article-title 43
###begin article-title 44
Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein
###end article-title 44
###begin article-title 45
###xml 86 91 <span type="species:ncbi:9606">human</span>
C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells
###end article-title 45
###begin article-title 46
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 62 65 <span type="species:ncbi:10116">rat</span>
C-peptide stimulates Na+, K+-ATPase activity via PKC alpha in rat medullary thick ascending limb
###end article-title 46
###begin article-title 47
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
###end article-title 47
###begin article-title 48
C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction
###end article-title 48
###begin article-title 49
###xml 193 204 <span type="species:ncbi:10116">Wistar rats</span>
Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats
###end article-title 49
###begin article-title 50
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus
###end article-title 50
###begin article-title 51
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients
###end article-title 51
###begin article-title 52
Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition
###end article-title 52
###begin article-title 53
C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
###end article-title 53
###begin article-title 54
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus
###end article-title 54
###begin article-title 55
###xml 85 88 <span type="species:ncbi:10116">rat</span>
C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat
###end article-title 55
###begin article-title 56
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity of renal tubule segments
###end article-title 56
###begin article-title 57
###xml 62 66 <span type="species:ncbi:10116">rats</span>
C-peptide fragments stimulate glucose utilization in diabetic rats
###end article-title 57
###begin article-title 58
Association of reduced red blood cell deformability and diabetic nephropathy
###end article-title 58
###begin article-title 59
Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition
###end article-title 59
###begin article-title 60
Red cell aggregation and red cell deformability in diabetes
###end article-title 60
###begin article-title 61
Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability
###end article-title 61
###begin article-title 62
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type I diabetes mellitus
###end article-title 62
###begin article-title 63
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 81 <span type="species:ncbi:9606">human</span>
C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells
###end article-title 63
###begin article-title 64
###xml 21 26 <span type="species:ncbi:9606">human</span>
C-peptide binding to human cell membranes: importance of Glu27
###end article-title 64
###begin article-title 65
Separate functional features of proinsulin C-peptide
###end article-title 65
###begin article-title 66
###xml 99 103 <span type="species:ncbi:10116">rats</span>
The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats
###end article-title 66
###begin article-title 67
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release from erythrocytes
###end article-title 67
###begin article-title 68
Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter
###end article-title 68
###begin article-title 69
Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream
###end article-title 69
###begin article-title 70
Red blood cells express a functional endothelial nitric oxide synthase
###end article-title 70
###begin article-title 71
###xml 98 102 <span type="species:ncbi:10116">rats</span>
Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro
###end article-title 71
###begin article-title 72
Effects of nitric oxide on red blood cell deformability
###end article-title 72
###begin article-title 73
###xml 80 88 <span type="species:ncbi:9606">patients</span>
C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients
###end article-title 73
###begin p 74
###xml 183 184 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 194 195 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 206 207 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Erythrocyte elongation index (EI) (%) +/- SD for erythrocytes from healthy controls (open columns) and type 1 diabetes patients (filled columns) at different levels of shear stress. *P < .05. **P < .01. ***P < .001 versus controls.
###end p 74
###begin p 75
###xml 29 30 29 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 444 445 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
Erythrocyte elongation index (EI) (%) +/- SD for erythrocytes from healthy controls and type 1 diabetes patients. The latter cells were incubated with C-peptide, hexapeptide (HP), and pentapeptide (PP) from the C-terminal region of C-peptide as well as a middle fragment (MF) and scrambled peptide (SCR, control). Results for combined incubation with PP and oubain or EDTA are also shown. Data are obtained at the shear stress level 1.2 Pa. ***P < .001 versus untreated erythrocytes from type 1 diabetes patients.
###end p 75
###begin p 76
Clinical characteristics of study subjects.
###end p 76
###begin p 77
Amino acid structure of C-peptide and C-peptide fragments used in this study.
###end p 77
###begin p 78
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Erythrocyte elongation index (EI) (%) in the shear stress range 0.6-12 Pa for different treatment groups, n = 23.
###end p 78
###begin p 79
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
 *P < .01 versus type 1 diabetes patients.
###end p 79

